PROTACs

  • Put your challenging affinity screening campaigns back on track — after you’ve tried everything else37:25

    Put your challenging affinity screening campaigns back on track — after you’ve tried everything else

    When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an

    Watch
  • How to build an effective protein degrader

    How to build an effective protein degrader

    Read
  • How to improve the function of your PROTAC degrader by understanding ternary complex formation59:35

    How to improve the function of your PROTAC degrader by understanding ternary complex formation

    Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target

    Watch
  • Why so many companies are betting on PROTACs as a superior therapeutic modality

    Why so many companies are betting on PROTACs as a superior therapeutic modality

    With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...

    Read
  • Rely on Dianthus to overcome roadblocks in your PROTAC characterizations

    Rely on Dianthus to overcome roadblocks in your PROTAC characterizations

    Read
  • ×

    Working with PROTACs?

    Sign up to receive the latest eBooks, product updates, event announcements, and more

    First Name
    Last Name
    Company Name
    Country
    State
    Province
    State
    Region
    State
    Canton
    Agree to Subscribe & Privacy Policy*
    *I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

    By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
    Thank you!
    Error - something went wrong!
  • Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust

    Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust

    Read
  • Improve your protein degrader design with new ways to discover E3 ligase ligands35:47

    Improve your protein degrader design with new ways to discover E3 ligase ligands

    Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat

    Watch
  • 10 terms to help you more easily understand targeted protein degradation

    10 terms to help you more easily understand targeted protein degradation

    Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...

    Read
  • Trying to characterize ternary complex formation and cooperativity?

    In-solution measurements will help

    Find out more
  • Protein degraders show promising results in drug development pipelines. See progress candidates have made.

    Protein degraders show promising results in drug development pipelines. See progress candidates have made.

    There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...

    Read
  • Discover tools to successfully characterize PROTAC binary and ternary complexes

    Read more
  • 9 Targeted Protein Degradation conferences you don’t want to miss in 2022

    9 Targeted Protein Degradation conferences you don’t want to miss in 2022

    With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...

    Read
  • For protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome

    For protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome

    Neurodegenerative diseases (ND) and cancer are the two major targets in the pipelines of companies focused on targeted protein degradation as a therapeutic modality. Proteins involved in NDs —...

    Read
  • Targeted protein degradation promises to lead the way to effective drugs for challenging targets

    Targeted protein degradation promises to lead the way to effective drugs for challenging targets

    Read
  • MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development

    MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development

    Read
  • Ddi1 is a ubiquitin-dependent protease

    Ddi1 is a ubiquitin-dependent protease

    Read
  • Are you building an effective protein degrader? 4 questions to ask yourself to find out

    Are you building an effective protein degrader? 4 questions to ask yourself to find out

    Protein degraders are getting a lot of attention for being a new and promising modality to treat diseases such as cancer or Alzheimer’s disease. Rather than inhibiting the function of a protein,...

    Read
  • ×

    Working with PROTACs?

    Sign up to receive the latest eBooks, product updates, event announcements, and more

    First Name
    Last Name
    Company Name
    Country
    State
    Province
    State
    Region
    State
    Canton
    Agree to Subscribe & Privacy Policy*
    *I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

    By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
    Thank you!
    Error - something went wrong!
  • Optimize the structure of your next round of PROTAC compounds by analyzing ternary binding affinities using Monolith

    Optimize the structure of your next round of PROTAC compounds by analyzing ternary binding affinities using Monolith

    Read
  • 6  protein degradation conferences in 2021 you can’t afford to miss

    6 protein degradation conferences in 2021 you can’t afford to miss

    Update: See what 2022 conferences you should watch for Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation...

    Read
  • Tackle the high-hanging fruits in challenging drug discovery pipelines17:10

    Tackle the high-hanging fruits in challenging drug discovery pipelines

    There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t

    Watch
  • Trying to characterize ternary complex formation and cooperativity?

    In-solution measurements will help

    Find out more
  • Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Read
  • Discover tools to successfully characterize PROTAC binary and ternary complexes

    Read more
  • What are PROTACs: the game-changing modality that promises to tackle undruggable proteins

    What are PROTACs: the game-changing modality that promises to tackle undruggable proteins

    Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity. Unfortunately, there are still many target proteins — as much as 85% of the human...

    Read
  • loading
    Loading more...